IP Library Patent Application 18019210
Patent Application
App. No. 18/019,210

METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/019,210
Abstract

The present disclosure provides a method for preventing and/or treating a damage to micro vascular integrity comprising administering to a subject, a composition comprising selected cannabinoid, thereby maintaining the microvascular integrity.

Claims (18)

1 . A method for preventing and/or treating damage to microvascular integrity, comprising administering to a subject in need thereof a composition comprising one or more cannabinoids, thereby preventing and/or treating the damage to microvascular integrity.

2 . The method of claim 1 , wherein the damage to microvascular integrity is due to the aging process, Diabetes Mellitus, Arteriosclerosis, chronic thromboembolic pulmonary hypertension (CTEPH), Portal Atresia (Hepatic Microvascular Dysplasia), nonalcoholic fatty liver disease (NAFLD), Chronic Kidney Disease, Small vessel disease. Polycystic ovarian syndrome, Chronic inflammation, or Traumatic Brain Injury (TBI).

3 . The method of claim 1 , wherein the one or more cannabinoids is administered in a dose range of about 0.01 mg to about 600 mg.

4 . The method of claim 1 , wherein the one or more cannabinoids is administered via an oral, vaginal, rectal, oral mucosal, nasal, sublingual, inhalational, topical, parenteral, intravenous, intramuscular, or subcutaneous route of administration.

5 . The method of claim 1 , wherein the one or more cannabinoids is tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabinol (CBN), Cannabigerol (CBG), Cannabichromene (CBC), Cannabicyclol (CBL), Cannabivarin (CBV), Tetrahydrocannabivarin (THCV), Cannabidivarin (CBDV), Cannabichromevarin (CBCV), Cannabigerovarin (CBGV) and Cannabigerol Monomethyl Ether (CBGM), Anandamide(AEA) and 2-Arachidonoylglycerol (2-AG), HU-210, HU-211, HU-308, HU-433, JWH-018, JWH-073, CP-47,497, JWH-200, cannabicyclohexanol, or any combination thereof.

6 . The method of claim 5 , wherein the one or more cannabinoids is derived from parts of a plant belonging to family Cannabaceae.

7 . The method of claim 6 , wherein the plant is Cannabis sativa, Cannabis indica , or Cannabis ruderalis , or hemp varieties thereof.

8 . The method of claim 5 , wherein the cannabinoid is THC.

9 . The method of claim 8 , wherein the THC is taken in a dosage of about 0.001 mg to about 0.5 mg.

10 . The method of claim 8 , wherein the THC is taken in a dosage of about 0.5 mg to about 2.5 mg.

11 . The method of claim 8 , wherein the THC is taken in a dosage of about 2.5 mg to about 10 mg.

12 . The method of claim 5 , wherein the cannabinoid is CBD.

13 . The method of claim 12 , wherein the CBD is taken in a dosage of about 0.1 mg to about 10 mg.

14 . The method of claim 12 , wherein the CBD is taken in a dosage of about 10 mg to about 100 mg.

15 . The method of claim 12 , wherein the CBD is taken in a dosage of about 100 mg to about 600 mg.

16 . The method of claim 5 , wherein the one or more cannabinoids is a plant extract containing said one or more cannabinoids.

17 . The method of claim 1 , wherein the subject is human.

18 - 34 . (canceled)

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2025
From: SCISPARC LTD.
To: NEUROTHERA LABS INC.
Reel/Frame 073090/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2025
From: SHMULEWITZ, ASCHER; ZULOFF-SHANI, ADI; BRENER, EPHRAIM
To: THERAPIX BIOSCIENCES LTD.
Reel/Frame 072747/0242 →
CHANGE OF NAME Recorded Oct 31, 2025
From: THERAPIX BIOSCIENCES LTD .
To: SCISPARC LTD.
Reel/Frame 073434/0656 →